US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Weight Loss Drugs

1,567.99

-10.0364-0.64%

Number of Gainers:- -

Number of Losers:7

Number of Flat:- -

PE:- -

High:1,590.89

Open:1,579.34

Low:1,558.46

Close:1,578.03

Volume:63.28M

Turnover:5.40B

Market Cap:1.63T

Float Cap:1.57T

Loading ...

Viking Therapeutics reports ‘positive’ results from maintenance study of VK2735

Viking Therapeutics Reports Vk2735 Maintenance Trial Keeps up to 97% of Weight Loss with Every-Other-Week Dosing

Viking Therapeutics, - up to 97% Weight Loss Maintained with Every-Other-Week Dosing for Three Months

THOMSON REUTERS

Viking Therapeutics Announces Positive Topline Results from Maintenance Study of Glp-1/Gip Agonist Vk2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens

THOMSON REUTERS

Viking Therapeutics, - Maintenance Dosing Shows Gi Adverse Event Rates Similar to Placebo

THOMSON REUTERS

Viking Therapeutics, - Reports 22% Placebo-Adj Weight Loss at Week 33 with Vk2735 17.5 Mg Weekly Dosing

THOMSON REUTERS

Novo Nordisk Investor Day Disappointed

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Invivyd (IVVD) and Humacyte (HUMA)

Market Chatter: Novo Nordisk CEO Eyes M&A to Fill Gaps in Drug Portfolio

MT Newswires Live

Novo Stock (NVO): Deutsche Bank Keeps Sell Rating, Says Growth Strategy ‘Underwhelming on Multiple Fronts’

Novo Nordisk (0QIU) Receives a Hold from Berenberg Bank

Novo Nordisk Investors Remain Nervous, but Share Drop an Overreaction

Sino Biopharmaceutical Stock Slips 1.4% in Hong Kong, Underperforms Competitors

Novo Nordisk's Underwhelming Investor Day Met with Punishing Response

Novo Nordisk's Share Fall After Investor Day Seems Harsh

Novo Nordisk Investor Day Offered Little to Excite

Novo Nordisk Highlights Building Blocks, but More Data Needed to Reassure Investors

Eli Lilly and Company Breaks Ground on $6.5 Billion Houston Manufacturing Site

MT Newswires Live

Eli Lilly: Breaks Ground on Fifth U.S. API Manufacturing Site in Houston

THOMSON REUTERS

Eli Lilly: Houston Facility to Manufacture Active Pharmaceutical Ingredients for Medicines Like Foundayo

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/stock/BK4599/news?page=13"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4599","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","market":"US","secType":"PLATE","nameCN":"Weight Loss Drugs","latestPrice":1567.9943,"timestamp":1790971199999,"preClose":1578.0306,"halted":0,"volume":63277927,"delay":0,"changeRate":-0.00636,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":-10.036377,"latestTime":"10-02 16:00:00 EDT","open":1579.339,"high":1590.8905,"low":1558.4647,"amount":5402065307.321307,"amplitude":0.020548,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":9.58996,"peRate":28.239741,"turnoverRate":0.005949,"increases":0,"decrements":7,"flats":0,"marketCap":1628153847712,"floatMarketCap":1570705071680},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4599\",,,,,undefined,":{"symbol":"BK4599","high":1590.8905,"amplitude":0.020548,"preClose":1578.0306,"low":1558.4647,"pbRate":"9.58996","latestPrice":1567.9943,"volume":63277927,"delay":0,"open":1579.339,"prevYearClose":1494.5856,"prevWeekClose":1622.7886,"prevMonthClose":1599.3274,"prevQuarterClose":1599.3274,"fiveDayClose":1622.7886,"twentyDayClose":1648.1235,"sixtyDayClose":1637.6415,"secType":"PLATE","market":"US","turnoverRate":0.005949,"peRate":28.239741,"marketCap":1628153847712,"floatMarketCap":1570705071680,"timestamp":1790971199999,"nameCN":"Weight Loss Drugs"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4599\",,,,undefined,":{"bkCode":"BK4599","up":0,"down":7,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4599\",pageSize:20,pageCount:13,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2669493381","title":"Viking Therapeutics reports ‘positive’ results from maintenance study of VK2735","url":"https://stock-news.laohu8.com/highlight/detail?id=2669493381","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669493381?lang=en_us&edition=fundamental","pubTime":"2026-09-22 19:10","pubTimestamp":1790075445,"startTime":"0","endTime":"0","summary":"Viking Therapeutics (VKTX) announced positive top-line results from the company’s maintenance study of VK2735, the company’s dual agonist of the gl...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/viking-therapeutics-reports-positive-results-from-maintenance-study-of-vk2735-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/viking-therapeutics-reports-positive-results-from-maintenance-study-of-vk2735-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4585","BK4588","THNR","VKTX","OZEM","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669179146","title":"Viking Therapeutics Reports Vk2735 Maintenance Trial Keeps up to 97% of Weight Loss with Every-Other-Week Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=2669179146","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669179146?lang=en_us&edition=fundamental","pubTime":"2026-09-22 19:05","pubTimestamp":1790075134,"startTime":"0","endTime":"0","summary":"Viking Therapeutics reports VK2735 maintenance trial keeps up to 97% of weight loss with every-other-week dosingViking Therapeutics reported positive topline results from a maintenance study of obesit","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nNDL3vJdWZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OZEM","BK4599","BK4585","BK4588","THNR","BK4139","VKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669514611","title":"Viking Therapeutics, - up to 97% Weight Loss Maintained with Every-Other-Week Dosing for Three Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2669514611","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669514611?lang=en_us&edition=fundamental","pubTime":"2026-09-22 19:05","pubTimestamp":1790075100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUABKSRFB:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4585","BK4599","VKTX","BK4588","OZEM","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669461111","title":"Viking Therapeutics Announces Positive Topline Results from Maintenance Study of Glp-1/Gip Agonist Vk2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens","url":"https://stock-news.laohu8.com/highlight/detail?id=2669461111","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669461111?lang=en_us&edition=fundamental","pubTime":"2026-09-22 19:05","pubTimestamp":1790075100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUABKSRFB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","BK4588","OZEM","VKTX","BK4139","BK4599","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669146116","title":"Viking Therapeutics, - Maintenance Dosing Shows Gi Adverse Event Rates Similar to Placebo","url":"https://stock-news.laohu8.com/highlight/detail?id=2669146116","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669146116?lang=en_us&edition=fundamental","pubTime":"2026-09-22 19:05","pubTimestamp":1790075100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUABKSRFB:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4599","BK4139","BK4585","BK4588","THNR","VKTX","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669112146","title":"Viking Therapeutics, - Reports 22% Placebo-Adj Weight Loss at Week 33 with Vk2735 17.5 Mg Weekly Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=2669112146","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669112146?lang=en_us&edition=fundamental","pubTime":"2026-09-22 19:05","pubTimestamp":1790075100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260922:nTUABKSRFB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4139","BK4585","THNR","BK4599","OZEM","VKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669451651","title":"Novo Nordisk Investor Day Disappointed","url":"https://stock-news.laohu8.com/highlight/detail?id=2669451651","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669451651?lang=en_us&edition=fundamental","pubTime":"2026-09-22 18:39","pubTimestamp":1790073540,"startTime":"0","endTime":"0","summary":"1038 GMT - Novo Nordisk's capital markets day announcements, including the diversification plan and a vague midterm sales target, disappointed investors, AlphaValue analyst Abhishek Raval writes. \"Against the backdrop of excessive dependency on a single molecule, aggressive and heavy diversification bets, along with impeccable commercial execution, are the need of the hour.\" However, the markets have their reservations, Raval says. The commercial success of oral Wegovy, some promising late-stage assets, and the firepower for acquisitions provide reasons to bet on Novo, which is available at a discount to peers, he adds. AlphaValue rates the Danish drugmaker's stock at buy with a 450 Danish kroner target price. Shares fall 0.2% to 259.40 kroner.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4532","NVOH","LU1093756168.USD","NVOC","IE00BZ1G4Q59.USD","LU0154236417.USD","PPH","IE00BKVL7J92.USD","BK4588","BK4585","LU1093756325.SGD","OZEM","BK4599","NVOX","THNR","NVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669143096","title":"Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Invivyd (IVVD) and Humacyte (HUMA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2669143096","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669143096?lang=en_us&edition=fundamental","pubTime":"2026-09-22 18:10","pubTimestamp":1790071809,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amgen (AMGN), Invivyd (IVVD) and Humacyte (HUMA). ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amgen-amgn-invivyd-ivvd-and-humacyte-huma-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-amgen-amgn-invivyd-ivvd-and-humacyte-huma-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0889565916.HKD","PJP","BBH","XBI","BIB","BK4534","LU2468319806.SGD","XLV","LU1571399168.USD","LU0029874061.USD","LU2089984988.USD","IE00BJJMRZ35.SGD","BK4599","HCSG","BK4588","LU0320765992.SGD","BK4585","IE0002141913.USD","LU0109394709.USD","LU2242646821.SGD","LU0868494617.USD","IE0009355771.USD","BK4137","LU1023059063.AUD","AMGN","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU1057294990.SGD","BK4539","LU0058720904.USD","LU0122379950.USD","LU1061106388.HKD","LU1983299246.USD","LABU","BK4533","LU0289739699.SGD","IBBQ","IVVD","PBE","LU0128526141.USD","BK4139","BK4566","LU2242652126.USD","HUMA","BK4563","SG9999001440.SGD","TBXU","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669713148","title":"Market Chatter: Novo Nordisk CEO Eyes M&A to Fill Gaps in Drug Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2669713148","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669713148?lang=en_us&edition=fundamental","pubTime":"2026-09-22 17:52","pubTimestamp":1790070723,"startTime":"0","endTime":"0","summary":"Novo Nordisk  Chief Executive Mike Doustdar said the pharmaceutical major is considering acquisitions to bolster its position in the weight-loss drug market, CNBC reported Tuesday, citing an interview.Doustdar said Novo Nordisk will look for weaknesses in its drug lineup and consider acquisitions of treatments that could help close those gaps, CNBC reported.Doustdar said that the market reaction to its new long-term strategy and growth targets showed that the company still has work to do in convincing some investors.Novo Nordisk did not immediately reply to MT Newswires' request for comment.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","NVOH","BK4532","NVOC","PPH","BK4585","NVO","BK4599","OZEM","LU0154236417.USD","NVOX","IE00BKVL7J92.USD","THNR","BK4007","LU1093756325.SGD","IE00BZ1G4Q59.USD","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669143804","title":"Novo Stock (NVO): Deutsche Bank Keeps Sell Rating, Says Growth Strategy ‘Underwhelming on Multiple Fronts’","url":"https://stock-news.laohu8.com/highlight/detail?id=2669143804","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669143804?lang=en_us&edition=fundamental","pubTime":"2026-09-22 17:43","pubTimestamp":1790070183,"startTime":"0","endTime":"0","summary":"Novo shares fell 7.96% to $39.80 on Monday after its growth strategy, disclosed at its Capital Markets Day in London, failed to impress investors\n...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/novo-stock-nvo-deutsche-bank-keeps-sell-rating-says-growth-strategy-underwhelming-on-multiple-fronts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/novo-stock-nvo-deutsche-bank-keeps-sell-rating-says-growth-strategy-underwhelming-on-multiple-fronts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1093756325.SGD","PPH","IE00BZ1G4Q59.USD","LU0154236417.USD","BK4588","THNR","LU1093756168.USD","NVO","BK4532","BK4585","BK4007","BK4599","NVOX","OZEM","NVOH","IE00BKVL7J92.USD","NVOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669486461","title":"Novo Nordisk (0QIU) Receives a Hold from Berenberg Bank","url":"https://stock-news.laohu8.com/highlight/detail?id=2669486461","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669486461?lang=en_us&edition=fundamental","pubTime":"2026-09-22 17:15","pubTimestamp":1790068532,"startTime":"0","endTime":"0","summary":"In a report released today, Kerry Holford from Berenberg Bank maintained a Hold rating on Novo Nordisk, with a price target of DKK305.00. Holford c...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/novo-nordisk-0qiu-receives-a-hold-from-berenberg-bank-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/novo-nordisk-0qiu-receives-a-hold-from-berenberg-bank-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PPH","BK4532","NVO","BK4588","NVOX","IE00BZ1G4Q59.USD","LU1093756168.USD","OZEM","BK4599","BK4007","LU0154236417.USD","BK4585","THNR","NVOC","LU1093756325.SGD","IE00BKVL7J92.USD","NVOH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669110697","title":"Novo Nordisk Investors Remain Nervous, but Share Drop an Overreaction","url":"https://stock-news.laohu8.com/highlight/detail?id=2669110697","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669110697?lang=en_us&edition=fundamental","pubTime":"2026-09-22 17:11","pubTimestamp":1790068260,"startTime":"0","endTime":"0","summary":"0909 GMT - Novo Nordisk's 8% share price fall following the investor day is an overreaction, but proves that investors remain nervous about 2027, with expected price pressure and CagriSema drug launch skepticism, Berenberg analysts write. The Novo story appears more interesting from 2028, with zenagamtide phase 3 data, CagriSema bone and muscle function data and multiple phase 1 and 2 readouts, the bank says. The event provided a comprehensive overview of the company's strategy, R&D pipeline and business operations, but offered only incremental strategic insights, it adds. The 2030 and 2035 sales ambitions were also outlined, which are broadly in line with expectations. Understanding the need to quickly diversify the portfolio ahead of U.S./EU semaglutide patent expiry early next decade, Novo aims to significantly speed up development and supplement the internal pipeline. Shares fall 0.7%.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ1G4Q59.USD","NVOC","LU1093756325.SGD","OZEM","NVOH","NVOX","PPH","BK4585","BK4588","BK4007","NVO","LU0154236417.USD","THNR","BK4599","LU1093756168.USD","BK4532","IE00BKVL7J92.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669511784","title":"Sino Biopharmaceutical Stock Slips 1.4% in Hong Kong, Underperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2669511784","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669511784?lang=en_us&edition=fundamental","pubTime":"2026-09-22 16:32","pubTimestamp":1790065920,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Sino Biopharmaceutical Ltd. slipped 1.4% to 5.84 Hong Kong dollars on what proved to be an all-around positive trading session for the Hong Kong stock market, with the Hang Seng Index rising 0.2% to 25087.75.Sino Biopharmaceutical Ltd. closed 32% short of its 52-week high of HK$8.56, which the company reached Sept. 23.The stock underperformed when compared to some of its competitors, as CSPC Pharmaceutical Group Ltd. rose 1.1% and Amgen Inc. remained unchanged.Trading volume totaled 87.2 million shares, compared to the 50-day average of 88.8 million shares.Data source: Dow Jones Market Data, FactSet","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU1571399168.USD","LU2242652126.USD","SG9999001440.SGD","IE00BFTCPJ56.SGD","LU2468319806.SGD","LU2089984988.USD","BK1521","BK4585","IE00BJJMRZ35.SGD","LU2242646821.SGD","IBBQ","BK1515","BK4581","AMGN","HK0000165453.HKD","IE00BZ08YS42.EUR","IE00B4R5TH58.HKD","LU0289739699.SGD","BK1589","IE00BZ08YR35.GBP","LU0058720904.USD","PBE","LU0122379950.USD","BK4566","LU0889565916.HKD","LU2112291526.USD","BK4588","BK4599","BK4534","IE0002141913.USD","LU0868494617.USD","LU1057294990.SGD","LU0320765992.SGD","IBB","01177","PJP","IE00BZ08YT58.USD","LU0109394709.USD","IE00B2B36J28.USD","LU1061106388.HKD","BK1191","TBXU","LU1023059063.AUD","IE00BJT1NW94.SGD","BBH","LU1983299246.USD","BIB","IE0009355771.USD","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669141741","title":"Novo Nordisk's Underwhelming Investor Day Met with Punishing Response","url":"https://stock-news.laohu8.com/highlight/detail?id=2669141741","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669141741?lang=en_us&edition=fundamental","pubTime":"2026-09-22 15:41","pubTimestamp":1790062860,"startTime":"0","endTime":"0","summary":"0740 GMT - Novo Nordisk's investor day underwhelmed on multiple fronts, relative to some of the more optimistic expectations heading into the event, Deutsche Bank analyst Emmanuel Papadakis writes. \"Whilst the event provided both a helpful and thorough review of the business outlook as well as a strategic refresh, it was met with a fairly punishing market response.\" The bank says there was largely a reiteration of familiar strategic messaging and the mid-term building blocks, in addition to somewhat underwhelming mid-term guidance. There was also nothing of substance in terms of clinical data or assets, and little clarity on M&A even though it clearly remains on the agenda, Deutsche Bank adds. The bank lowers its stock target price to 245 Danish kroner from 265 kroner and retains its sell rating. Shares fall 0.6% to 258.50 kroner.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","NVO","LU1093756168.USD","LU0154236417.USD","PPH","BK4007","NVOC","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","BK4532","OZEM","LU1093756325.SGD","NVOH","BK4599","BK4585","NVOX","THNR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669116407","title":"Novo Nordisk's Share Fall After Investor Day Seems Harsh","url":"https://stock-news.laohu8.com/highlight/detail?id=2669116407","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669116407?lang=en_us&edition=fundamental","pubTime":"2026-09-22 14:16","pubTimestamp":1790057760,"startTime":"0","endTime":"0","summary":"0616 GMT - Novo Nordisk's 8% share decline following the Wegovy maker's investor day on Monday suggests investors weren't convinced about its growth plans, but this seems like a somewhat harsh reaction, Jyske Bank's Henrik Hallengreen Laustsen writes. \"The strategy and its key components appear sound, if not impressive.\" However, following several disappointments from Novo, the market wants to see concrete clinical and commercial evidence, Jyske Bank adds. Novo presented ambitions for industry-level growth through 2030 and stable margins, which seemed slightly underwhelming relative to market expectations, the bank says. It maintains its hold rating on the stock with a 330 Danish kroner target price.Jyske Bank cites uncertainty on growth prospects, pressure from semaglutide's 2032 patent expiry, fair valuation, and limited near-term news flow. Shares closed Monday at 260 kroner.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0154236417.USD","BK4532","IE00BKVL7J92.USD","BK4588","BK4585","LU1093756168.USD","NVO","NVOC","BK4007","NVOH","OZEM","THNR","NVOX","LU1093756325.SGD","BK4599","IE00BZ1G4Q59.USD","PPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669115129","title":"Novo Nordisk Investor Day Offered Little to Excite","url":"https://stock-news.laohu8.com/highlight/detail?id=2669115129","media":"Dow Jones","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669115129?lang=en_us&edition=fundamental","pubTime":"2026-09-22 13:40","pubTimestamp":1790055600,"startTime":"0","endTime":"0","summary":"0540 GMT - Novo Nordisk's capital markets day offered little to change Citi's cautious view, with topline growth ambitions in line with consensus but margins below expectations. The company is positioning for the post-semaglutide era through more than five planned multi-blockbuster launches by 2030 and more than 150 billion Danish kroner of pipeline sales by 2035, which is largely reflected in consensus, Citi says. Updated oral obesity capacity and more than 20 Wegovy pill market launches in 2027 are encouraging, but execution is key. Novo also intends to broaden growth beyond obesity and diabetes into cardiovascular, liver, blood, and endocrine disorders, while a 2027 launch of CagriSema is a key opportunity to beat consensus, Citi adds. \"M&A focus remains bolt-on but management did not rule out a large transaction, creating some inherent risk.\"","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVOH","PPH","BK4585","BK4532","IE00BZ1G4Q59.USD","LU1093756325.SGD","NVOX","BK4588","OZEM","IE00BKVL7J92.USD","BK4007","NVO","NVOC","THNR","BK4599","LU0154236417.USD","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669111591","title":"Novo Nordisk Highlights Building Blocks, but More Data Needed to Reassure Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2669111591","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669111591?lang=en_us&edition=fundamental","pubTime":"2026-09-22 13:30","pubTimestamp":1790055000,"startTime":"0","endTime":"0","summary":"0527 GMT - Novo Nordisk used its investor day to highlight potential building blocks that underpin mid-term growth expectations, but more data is needed to increase investor confidence, J.P. Morgan analysts write. The company provided mid-term targets for topline growth from 2026-30 in the mid-single-digit range and an expectation for adjusted operating profit margins to remain broadly stable. These targets largely underpin consensus expectations for sales, but depend on the Wegovy oral pill and CagriSema rollouts, and delivery of a competitive zenagamtide obesity and weight-loss drug profile in phase-3 trials in 2028, the bank adds. The company highlighted three further oral obesity products beyond Wegovy that it expects will further drive its market share in this segment. Shares fell 7.7% Monday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4599","BK4588","LU1093756168.USD","NVOH","OZEM","IE00BZ1G4Q59.USD","THNR","BK4007","LU0154236417.USD","NVO","LU1093756325.SGD","NVOC","NVOX","PPH","IE00BKVL7J92.USD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669619560","title":"Eli Lilly and Company Breaks Ground on $6.5 Billion Houston Manufacturing Site","url":"https://stock-news.laohu8.com/highlight/detail?id=2669619560","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669619560?lang=en_us&edition=fundamental","pubTime":"2026-09-22 05:55","pubTimestamp":1790027717,"startTime":"0","endTime":"0","summary":"Eli Lilly and Company  said Monday it has broken ground on a $6.5 billion manufacturing facility in Houston, Texas, that will produce its oral GLP-1 drug Foundayo along with other small-molecule medicines and advanced therapeutics.Lilly said the facility is expected to create more than 600 high-wage jobs and roughly 4,000 construction jobs.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0889565916.HKD","IE00B4R5TH58.HKD","MEDX","LU2264538146.SGD","IE00BJJMRX11.SGD","LU2750360641.GBP","LLYX","LU1623119135.USD","LU2023250330.USD","LLII","LU0820561909.HKD","LU2361044865.SGD","SGXZ57979304.SGD","CANC","LU0466842654.USD","SG9999015952.SGD","LU1988902786.USD","LU2168564222.USD","LU2361044949.HKD","LU0708995401.HKD","LU1232071149.USD","IYH","LU0943347566.SGD","SG9999001176.SGD","SG9999015978.USD","BK4007","LU2106854487.HKD","TMED","IE00B4JS1V06.HKD","LU2237443382.USD","IE00B2B36J28.USD","LU0256863902.USD","LU1057294990.SGD","LU1064131342.USD","LU1989771016.USD","LU2471134523.USD","LU2552382132.HKD","LU1868836591.USD","IE00BK4W5M84.HKD","IE00BKDWB100.SGD","LU0882574139.USD","LU2462591350.SGD","LU0061475181.USD","SGXZ51526630.SGD","LU0823434740.USD","WDNA","LU2063271972.USD","SG9999014906.USD","LU2237443465.HKD","LU2471134952.CNY","LU1868837136.USD","THNR","LU2750360997.AUD","IE00BN29S564.USD","SG9999017495.SGD","LU0097036916.USD","LU2417539215.USD","BK4533","LU1093756168.USD","LU2361045086.USD","PPH","LU0353189680.USD","IE00BJJMRY28.SGD","LU0354030511.USD","LU0106261372.USD","LU0238689110.USD","OZEM","LU1023059063.AUD","LU2471134879.HKD","ELIL","IE0002141913.USD","IE00BFTCPJ56.SGD","LU0964807845.USD","BK4599","LU0683600562.USD","LU0432979614.USD","IE00BWXC8680.SGD","LU1720051017.SGD","LU0820562030.AUD","LU1868837300.USD","LU2456880835.USD","LU0225283273.USD","IE0004445239.USD","LU2491050154.USD","LU2552382058.USD","FHLC","LU1291159041.SGD","LU2471134796.USD","BK4516","LU1551013425.SGD","LU2357305700.SGD","LU1868836757.USD","LU2111349929.HKD","LU2087625088.SGD","LU2168564495.EUR","LU0640476718.USD","LU0094547139.USD","LU1127390331.HKD","LU2265009873.SGD","LU2237443622.USD","IE0009355771.USD","LU2746668461.USD","LU2896262040.SGD","ELIS","IE00BFSS8Q28.SGD","LU2756315664.SGD","TRUH","LU2023251221.USD","LU0320765992.SGD","LU0323591593.USD","IE0001KFT4U8.USD","SG9999014914.USD","LU1280957306.USD","LU2462157665.USD","LU2089984988.USD","LU2168564149.EUR","CURE","IXJ","LU1035775433.USD","LU0689472784.USD","IE0004445015.USD","LU2756315318.SGD","LU2237443895.HKD","SG9999001176.USD","LU0234572021.USD","LU2552382215.SGD","LU1917777945.USD","LU0174119429.USD","LU0096364046.USD","LU2236285917.USD","LU1868836914.USD","LU2237443978.SGD","LU0471298694.HKD","LU0385154629.USD","LU0823416689.USD","MEDI","SG9999018865.SGD","LU0203201768.USD","LU0256863811.USD","LU0786609619.USD","LU2213496289.HKD","IE00B7KXQ091.USD","LU1551013342.USD","LU1629891620.HKD","LU0109391861.USD","LU1691799644.USD","LU1712237335.SGD","SG9999013999.USD","LU0158827948.USD","LU0820561818.USD","LU1061106388.HKD","LU0058720904.USD","LU0353189763.USD","LU0354030438.USD","MHIP","HRTS","LU0456855351.SGD","LU1814569148.SGD","LU1093756325.SGD","LU2237443549.SGD","XLV","LU1979441026.SGD","LU1974910355.USD","LU0133085943.USD","RXL","LU2168563687.JPY","LU1323610961.USD","LU1366192091.USD","SG9999014880.SGD","LU0203202063.USD","LU0471298777.SGD","GB00BDT5M118.USD","LU2491049909.HKD","LU0823434583.USD","BK4585","IE00BJT1NW94.SGD","LU0266013472.USD","SG9999015986.USD","IE00BK4W5L77.USD","LU2360106947.USD","ILDR","LU1267930730.SGD","IHE","LU0006306889.USD","LU2108987350.USD","LU2089284900.SGD","LU0122379950.USD","LU2237438978.USD","LU2324357040.USD","IE00B1XK9C88.USD","LU0787776722.HKD","LU2468319806.SGD","GDOC","LU1069344957.HKD","LU1548497426.USD","LU2271345857.HKD","LU2602419157.SGD","LU2461242641.AUD","LU0289739699.SGD","LU2746668974.SGD","SGXZ31699556.SGD","LU0672654240.SGD","IE00BFSS7M15.SGD","LU0882574055.USD","IE00BJLML261.HKD","IE00BJJMRZ35.SGD","LU1804176565.USD","FTXH","LU2112291526.USD","IE00B775H168.HKD","LU2023250504.SGD","SG9999018857.SGD","IE00BKPKM429.USD","IE00B1BXHZ80.USD","LU2211815571.USD","LU0079474960.USD","IE0005OL40V9.USD","LU1720051108.HKD","LU0345770993.USD","PJP","BK4588","LU0210536198.USD","LU0417517546.SGD","LU0158827781.USD","LU2028103732.USD","LU1983299246.USD","SGXZ99366536.SGD","LU2089283258.USD","SG9999015945.SGD","VHT","LU0345770308.USD","LU1145028129.USD","AGNG","SG9999014898.SGD","SGXZ81514606.USD","LU0316494557.USD","LU0109394709.USD","LLY","BK4581","LLYZ","LU0114720955.EUR","LU0320765059.SGD","LU2491050071.SGD","LU0198837287.USD","LU2168564065.EUR","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669955941","title":"Eli Lilly: Breaks Ground on Fifth U.S. API Manufacturing Site in Houston","url":"https://stock-news.laohu8.com/highlight/detail?id=2669955941","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669955941?lang=en_us&edition=fundamental","pubTime":"2026-09-22 05:44","pubTimestamp":1790027083,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nFWN45D0IB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1548497426.USD","LU2028103732.USD","LU2896262040.SGD","LU1868836591.USD","VHT","SG9999015978.USD","LU1127390331.HKD","IE00BFSS8Q28.SGD","LU0225283273.USD","LU0316494557.USD","LU2168563687.JPY","LU2461242641.AUD","LU0238689110.USD","LU0256863902.USD","LU1804176565.USD","LU1814569148.SGD","IE00B4R5TH58.HKD","LU1917777945.USD","LU1989771016.USD","FHLC","LU2471134523.USD","LU2108987350.USD","MEDI","ELIL","SG9999017495.SGD","IE00B1BXHZ80.USD","LU2417539215.USD","LU2471134952.CNY","LU1629891620.HKD","BK4588","WDNA","BK4599","LU2236285917.USD","LU1145028129.USD","IE00BWXC8680.SGD","LU0320765992.SGD","LU2552382215.SGD","LU2602419157.SGD","LU2750360997.AUD","SG9999018865.SGD","LU2324357040.USD","LU2087625088.SGD","IE00BJJMRX11.SGD","LU0096364046.USD","LU0820561818.USD","SG9999015986.USD","LU1974910355.USD","LU2746668974.SGD","LU0353189680.USD","LU0345770993.USD","LU2237438978.USD","LU1691799644.USD","LU2357305700.SGD","LU2456880835.USD","LU1712237335.SGD","SG9999015952.SGD","LU0820562030.AUD","IE00BJT1NW94.SGD","LU2023251221.USD","LU2471134796.USD","IE0009355771.USD","LU2361045086.USD","LU0114720955.EUR","LU0385154629.USD","LU2468319806.SGD","IE00BJJMRY28.SGD","BK4585","IE00BJJMRZ35.SGD","CURE","IE00B4JS1V06.HKD","IYH","LU0882574055.USD","LU2211815571.USD","LU2361044949.HKD","IE00BK4W5M84.HKD","LU0432979614.USD","LU2237443622.USD","LU1093756325.SGD","LU2213496289.HKD","LU2750360641.GBP","LU0174119429.USD","LU0471298777.SGD","LU0820561909.HKD","LU0109391861.USD","LU0943347566.SGD","LU2237443465.HKD","TRUH","IE00BFSS7M15.SGD","LLII","LU1232071149.USD","CANC","LU0122379950.USD","LU2471134879.HKD","LU2746668461.USD","MEDX","SG9999014898.SGD","SG9999014906.USD","LU2271345857.HKD","LLYZ","BK4007","IE0004445015.USD","LU2168564222.USD","LU0079474960.USD","LU0823434583.USD","LU0354030438.USD","LU0109394709.USD","IE00BKDWB100.SGD","LU1064131342.USD","LU2264538146.SGD","LU2462591350.SGD","LU0353189763.USD","LU1868837300.USD","SGXZ51526630.SGD","LU1267930730.SGD","LU2265009873.SGD","LU1061106388.HKD","LU1623119135.USD","ELIS","LU0471298694.HKD","LLY","LU2089284900.SGD","PPH","LU0640476718.USD","LU2237443549.SGD","LU0345770308.USD","LU1720051017.SGD","LU0266013472.USD","IE00B775H168.HKD","LU1366192091.USD","OZEM","LU0689472784.USD","LU0097036916.USD","LU0708995401.HKD","TMED","LU2089984988.USD","LU2168564065.EUR","LU0210536198.USD","LU2552382132.HKD","LU2756315318.SGD","RXL","LU0964807845.USD","SGXZ81514606.USD","LU2237443895.HKD","LU2106854487.HKD","LU1035775433.USD","SGXZ31699556.SGD","LLYX","LU0354030511.USD","LU1988902786.USD","LU0787776722.HKD","MHIP","GDOC","LU2063271972.USD","LU0158827781.USD","BK4534","LU0323591593.USD","FTXH","LU2023250504.SGD","LU0061475181.USD","SG9999001176.USD","GB00BDT5M118.USD","XLV","LU1323610961.USD","JDOC","THNR","SGXZ99366536.SGD","IXJ","LU2111349929.HKD","LU0417517546.SGD","AGNG","SGXZ57979304.SGD","LU1069344957.HKD","LU0823434740.USD","LU1983299246.USD","IE00BJLML261.HKD","IE00BN29S564.USD","LU2360106947.USD","BK4533","LU1093756168.USD","IE00B1XK9C88.USD","LU1551013342.USD","LU2089283258.USD","SG9999013999.USD","IE00BFTCPJ56.SGD","LU0203202063.USD","SG9999014880.SGD","IE0004445239.USD","LU0203201768.USD","LU0256863811.USD","LU0882574139.USD","LU0158827948.USD","HRTS","LU1868836914.USD","BK4581","IE00BK4W5L77.USD","LU2168564149.EUR","LU0786609619.USD","ILDR","LU0289739699.SGD","LU0133085943.USD","LU2552382058.USD","LU0058720904.USD","LU0456855351.SGD","LU0672654240.SGD","LU2168564495.EUR","IE00BKPKM429.USD","LU2023250330.USD","IE00B7KXQ091.USD","LU0889565916.HKD","LU2112291526.USD","LU2491049909.HKD","LU2237443382.USD","LU0198837287.USD","LU1868836757.USD","IE0002141913.USD","SG9999014914.USD","IE0001KFT4U8.USD","LU1057294990.SGD","LU1280957306.USD","LU1551013425.SGD","SG9999018857.SGD","LU0823416689.USD","LU0683600562.USD","PJP","LU2361044865.SGD","SG9999015945.SGD","LU0320765059.SGD","LU1979441026.SGD","LU1291159041.SGD","IE0005OL40V9.USD","LU1720051108.HKD","LU2237443978.SGD","LU2491050154.USD","LU0006306889.USD","LU2756315664.SGD","LU0466842654.USD","LU2491050071.SGD","IHE","IE00B2B36J28.USD","LU1868837136.USD","BK4516","LU0234572021.USD","LU2462157665.USD","LU0106261372.USD","SG9999001176.SGD","LU1023059063.AUD","LU0094547139.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669597195","title":"Eli Lilly: Houston Facility to Manufacture Active Pharmaceutical Ingredients for Medicines Like Foundayo","url":"https://stock-news.laohu8.com/highlight/detail?id=2669597195","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669597195?lang=en_us&edition=fundamental","pubTime":"2026-09-22 05:44","pubTimestamp":1790027083,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nFWN45D0IB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE0009355771.USD","LU0787776722.HKD","SG9999018865.SGD","ILDR","BK4516","BK4599","ELIS","LU1983299246.USD","LU2237443622.USD","SGXZ81514606.USD","LU2462157665.USD","LU2168564149.EUR","LU2089284900.SGD","LU2168564065.EUR","LU1623119135.USD","LU2023250330.USD","SG9999015952.SGD","IE00B1XK9C88.USD","LU1720051017.SGD","LU0256863902.USD","LU2750360641.GBP","SGXZ31699556.SGD","PJP","MEDX","LU0823416689.USD","LU0109391861.USD","SG9999017495.SGD","LU1712237335.SGD","LU0006306889.USD","GB00BDT5M118.USD","LU0174119429.USD","LU1291159041.SGD","SG9999013999.USD","LU0786609619.USD","LU2471134879.HKD","LU1232071149.USD","LU1868837300.USD","SG9999014906.USD","THNR","LU0354030511.USD","AGNG","IE00B775H168.HKD","LU2471134523.USD","LU2471134796.USD","LU2063271972.USD","LU0708995401.HKD","IE00BFSS8Q28.SGD","LU2106854487.HKD","LU2491049909.HKD","SG9999014880.SGD","LU2324357040.USD","LU2746668461.USD","LU1551013425.SGD","LU0198837287.USD","LU0061475181.USD","IE00B4JS1V06.HKD","LU1366192091.USD","IE00BK4W5M84.HKD","IE0004445015.USD","IE00BKDWB100.SGD","LU0432979614.USD","LU1974910355.USD","LU0097036916.USD","LU2361045086.USD","LU2111349929.HKD","LU2211815571.USD","SG9999015978.USD","IE00BFSS7M15.SGD","LU0203202063.USD","LU2089283258.USD","LU0683600562.USD","LU0820561909.HKD","LU0320765059.SGD","LU1323610961.USD","LU1093756325.SGD","SGXZ57979304.SGD","OZEM","LU2552382215.SGD","LU0820562030.AUD","HRTS","LLYX","LU1548497426.USD","LU0158827781.USD","LU0210536198.USD","LU0079474960.USD","LLII","LU0385154629.USD","IE00BJJMRY28.SGD","CURE","LU1551013342.USD","CANC","LU0466842654.USD","LU1061106388.HKD","LU2357305700.SGD","IHE","LU0417517546.SGD","LU2746668974.SGD","LU0234572021.USD","LU0456855351.SGD","SG9999014898.SGD","LU2360106947.USD","LU0889565916.HKD","LU1280957306.USD","LLY","LU1804176565.USD","IE00BJJMRZ35.SGD","IE0001KFT4U8.USD","BK4534","LU1145028129.USD","LU0823434583.USD","LU1023059063.AUD","LU1868836757.USD","LU0289739699.SGD","LU0345770308.USD","LU0820561818.USD","LU1720051108.HKD","LU1127390331.HKD","LU2417539215.USD","LU2552382132.HKD","LU2750360997.AUD","XLV","LU0225283273.USD","MEDI","TMED","IE00BFTCPJ56.SGD","LU0943347566.SGD","SG9999015945.SGD","LU2087625088.SGD","BK4588","IE00BK4W5L77.USD","LU0114720955.EUR","LU1035775433.USD","LU2756315664.SGD","LU1267930730.SGD","LU2552382058.USD","LU1814569148.SGD","LU2023250504.SGD","IE00BJJMRX11.SGD","LU2471134952.CNY","LU0471298777.SGD","LU1868836591.USD","LU2236285917.USD","VHT","LU0094547139.USD","LU1691799644.USD","IE00B4R5TH58.HKD","LU0203201768.USD","LU0238689110.USD","BK4533","LU1917777945.USD","LU0256863811.USD","MHIP","LU2361044949.HKD","LU2237438978.USD","LU2462591350.SGD","SGXZ99366536.SGD","IE00B7KXQ091.USD","LU2089984988.USD","LU2264538146.SGD","LU2491050154.USD","LU1069344957.HKD","JDOC","LU2602419157.SGD","LU2108987350.USD","SG9999001176.USD","LU2112291526.USD","LU1988902786.USD","BK4007","LU2237443382.USD","LU2271345857.HKD","IE00BKPKM429.USD","SG9999015986.USD","IYH","FTXH","LU1629891620.HKD","LU2028103732.USD","LU0058720904.USD","LU2213496289.HKD","LU0158827948.USD","LU0640476718.USD","LU1868836914.USD","LU2237443895.HKD","LU2265009873.SGD","LU1093756168.USD","LU2756315318.SGD","LU0323591593.USD","LU2168564222.USD","IE00BN29S564.USD","WDNA","FHLC","IE0002141913.USD","LU0882574139.USD","SG9999018857.SGD","SG9999014914.USD","IE00B2B36J28.USD","LU2237443465.HKD","LU0354030438.USD","LU0672654240.SGD","LU2168564495.EUR","LLYZ","LU1989771016.USD","IXJ","LU0689472784.USD","IE00BWXC8680.SGD","LU0106261372.USD","IE0004445239.USD","LU0823434740.USD","SGXZ51526630.SGD","LU0964807845.USD","LU2468319806.SGD","LU2896262040.SGD","PPH","LU2491050071.SGD","LU0109394709.USD","LU0882574055.USD","TRUH","LU2456880835.USD","LU2237443549.SGD","LU0133085943.USD","BK4585","IE00B1BXHZ80.USD","LU1057294990.SGD","IE00BJLML261.HKD","IE0005OL40V9.USD","IE00BJT1NW94.SGD","LU0122379950.USD","LU2168563687.JPY","LU2237443978.SGD","LU2023251221.USD","LU2461242641.AUD","LU0266013472.USD","GDOC","LU1064131342.USD","LU1868837136.USD","RXL","LU1979441026.SGD","LU0096364046.USD","LU0353189763.USD","LU0353189680.USD","SG9999001176.SGD","LU0345770993.USD","LU0320765992.SGD","LU0316494557.USD","LU0471298694.HKD","LU2361044865.SGD","BK4581","ELIL"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":15,"pageCount":13,"totalSize":297,"code":"91000000","status":"200"}]}}